



**PRESS RELEASE  
REGULATED INFORMATION**

## **Information on the total number of voting rights and shares**

**Mont-Saint-Guibert (Belgium), 28<sup>th</sup> October 2020, 18h CET** – In accordance with article 15 of the Act of 2<sup>nd</sup> May 2007 on the disclosure of large shareholdings, **Nyxoaah S.A.** publishes the below information following the issue of 23,500 new shares on 28 October 2020 pursuant to the exercise of warrants

- Share capital: EUR 3,796,047.64
- Total number of securities carrying voting rights: 22,097,609 (all ordinary shares)
- Total number of voting rights (= denominator): 22,097,609 (all relating to ordinary shares)
- Number of rights to subscribe to securities carrying voting rights not yet issued:
  - 161 “2013 ESOP Warrants” issued on 3 May 2013 and 23 December 2014, entitling their holders to subscribe for a total number of 80,500 securities carrying voting rights (all ordinary shares);
  - 435 “2016 ESOP Warrants” issued on 3 November 2016, entitling their holders to subscribe for a total number of 217,500 securities carrying voting rights (all ordinary shares);
  - 319 “2018 ESOP Warrants” issued on 12 December 2018, entitling their holders to subscribe for a total number of 159,500 securities carrying voting rights (all ordinary shares); and
  - 550,000 “2020 ESOP Warrants” issued on 21 February 2020, entitling their holders to subscribe for a total number of 550,000 securities carrying voting rights (all ordinary shares).

\*

\* \*

**- Ends -**

**For further information, please contact:**

**Nyxoaah**

Fabian Suarez, CFO

[corporate@nyxoaah.com](mailto:corporate@nyxoaah.com)

+32 (0)10 22 24 55

## About Nyxoah

Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services for sleep disordered breathing conditions. Nyxoah's lead solution is the Genio<sup>®</sup> system, a CE-validated, user-centered, next generation hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk<sup>1</sup> and comorbidities including cardiovascular diseases, depression and stroke.

Following successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio<sup>®</sup> system received its European CE Mark in March 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, and a post-marketing ELISA study in Europe to confirm the long-term safety and efficacy of the Genio<sup>®</sup> system.

For more information, please visit [www.nyxoah.com](http://www.nyxoah.com).

**Caution** – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

---

<sup>1</sup> Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen-Year Follow-up of the Wisconsin Sleep Cohort, *Sleep*. 2008 Aug 1; 31(8): 1071–1078.